In December this year, evitria AG reached a memorable milestone in its 13-year history: since their founding, the antibody and protein expression service provider has purified 20,000 antibodies and proteins, supplying researchers and biopharma companies worldwide with tailor-made biologicals.
“This December marks an important step for the entire team at evitria AG. Since 2010, we have become an internationally recognized and valued partner for custom-made antibody, custom recombinant antibody and protein products. Today, we are proud to be one of the largest and fastest-growing custom transient antibody and protein service providers”, states Richard Park, Global Head of Client Relations & Business Development at Swiss-based evitria.
Not only has the company purified a total of 20,000 antibodies for various purposes, but evitria AG has also completed more than 120,000 transfections. Among the full range of custom biologicals, there are recombinant antibodies as well as afucosylated and Fc-silenced antibodies for therapeutics research as well as assay and commercial diagnostic development.
Nevertheless, evitria AG continues to expand its services. With a representative soon to be responsible for the APAC market, the company understands the need to be true partners to its clients – listening to their needs and providing customized solutions most suitable for each client, only made possible by the decade-plus of experience in this specific field.
Richard Park emphasizes how effective such collaborations can prove to be and concludes: “We are proud and thankful for the trust that partners have shown to evitria in recent years. This has allowed us to embark on an incredible growth journey that we are excited to continue together with our partners worldwide. Stay tuned throughout 2023 as we roll out exciting updates that will no-doubt benefit our global partnerships!”